# A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-

Source: https://onco.cc/trials/nct05458297/  
OnCo record `nct05458297` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zilovertamab vedotin, Nemtabrutinib in mantle cell lymphoma and follicular lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) is a phase 2 interventional study registered as NCT05458297 by Merck Sharp & Dohme LLC, with 189 participants planned, started 2022-07-21 and due to reach its primary completion in 2029-05-17. Interventions recorded: Zilovertamab vedotin, Nemtabrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05458297
- Phase: 2
- Setting: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 189

## Sources

- ClinicalTrials.gov NCT05458297: https://clinicaltrials.gov/study/NCT05458297

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05458297.json